Unichem Laboratories' Q4 FY 2025-26 Quarterly Results

Result Summary

• Unichem Laboratories Ltd reported a 12.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 0.4%.
• Its expenses for the quarter were up by 10.2% QoQ and 5.3% YoY.
• The net profit decreased 95.9% QoQ and decreased 79.4% YoY.
• The earnings per share (EPS) of Unichem Laboratories Ltd stood at 1.55 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Unichem Laboratories Ltd is a prominent pharmaceutical company engaged in the development, manufacturing, and marketing of pharmaceutical formulations. The company operates within the pharmaceutical industry, focusing on creating a diverse range of products to cater to various medical needs. The company has a robust portfolio that includes both branded and generic formulations, which are distributed in both domestic and international markets. As of the data available up to October 2023, there have been no specific major developments recorded for Unichem Laboratories Ltd that would significantly alter this overview.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), Unichem Laboratories Ltd reported a total income of ₹598.59 crores. This reflects a quarter-over-quarter (QoQ) increase of 12.3% compared to ₹532.97 crores in the third quarter of FY26 (Q3FY26). Year-over-year (YoY), there is a marginal increase of 0.4% from ₹596.43 crores in the fourth quarter of FY25 (Q4FY25). The steady YoY growth suggests that the company has maintained its revenue levels despite the various challenges that could be present in the market. The QoQ increase might indicate a positive short-term performance trend in income.

Profitability

For Q4FY26, Unichem Laboratories Ltd recorded a Profit Before Tax (PBT) of ₹18.79 crores, indicating a significant QoQ decrease of 93.6% from ₹293.43 crores in Q3FY26. Additionally, the PBT shows a YoY decline of 67.5% from ₹57.80 crores in Q4FY25. After accounting for tax expenses amounting to ₹7.88 crores, the Profit After Tax (PAT) stood at ₹10.91 crores for Q4FY26, which is a 95.9% drop QoQ and a 79.4% decrease YoY from ₹52.97 crores in Q4FY25. Earnings Per Share (EPS) also followed this trend, decreasing to ₹1.55 from ₹37.47 in Q3FY26 and from ₹7.50 in Q4FY25, reflecting both QoQ and YoY declines of 95.9% and 79.3%, respectively.

Operating Metrics

Total expenses for Unichem Laboratories Ltd in Q4FY26 amounted to ₹567.44 crores, which is an increase of 10.2% QoQ from ₹515.06 crores in Q3FY26 and a 5.3% rise YoY from ₹538.63 crores in Q4FY25. This increase in expenses, in conjunction with the trends in income and profitability, suggests a dynamic operational environment. A deeper analysis of the company's operational efficiency and cost management strategies might be warranted. While the report does not provide specific operational ratios such as P/E or current ratio, these metrics would typically be calculated based on broader financial data not included here.